Identification of potential therapeutic drugs targeting core genes for systemic lupus erythematosus (SLE) and coexisting COVID-19: Insights from bioinformatic analyses

被引:0
作者
Chen, Chao [1 ]
Zhang, Hongjian [2 ]
Lin, Yanbin [2 ]
Lu, Meiqi [2 ]
Liao, Quan [2 ]
Zhang, Shichao [2 ]
Chen, Weibin [2 ]
Zheng, Xiongwei [2 ]
Li, Yunpeng [2 ]
Ding, Rui [2 ]
Wan, Zheng [2 ,3 ]
机构
[1] Huaqiao Univ, Inst Genom, Sch Med, Xiamen, Peoples R China
[2] Xiamen Univ, Zhongshan Hosp, Sch Med, Dept Oncol & Vasc Intervent Radiol, Xiamen, Fujian, Peoples R China
[3] Xiamen Univ, Zhongshan Hosp, Sch Med, Dept Oncol & Vasc Intervent Radiol, Xiamen 361000, Fujian, Peoples R China
关键词
bioinformatic; differentially expressed genes; severe coronavirus disease 2019 (COVID-19); systemic lupus erythematosus (SLE); targeted drugs; IMMUNITY; CD4(+);
D O I
10.1002/iid3.1087
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
ObjectiveSystemic lupus erythematosus (SLE) patients are at risk during the COVID-19 pandemic, yet the underlying molecular mechanisms remain incompletely understood. This study sought to analyze the potential molecular connections between COVID-19 and SLE, employing a bioinformatics approach to identify effective drugs for both conditions.MethodsThe data sets GSE100163 and GSE183071 were utilized to determine share differentially expressed genes (DEGs). These DEGs were later analyzed by various bioinformatic methods, including functional enrichment, protein-protein interaction (PPI) network analysis, regulatory network construction, and gene-drug interaction construction.ResultsA total of 50 common DEGs were found between COVID-19 and SLE. Gene ontology (GO) functional annotation revealed that "immune response," "innate immune response," "plasma membrane," and "protein binding" were most enriched in. Additionally, the pathways that were enriched include "Th1 and Th2 cell differentiation." The study identified 48 genes/nodes enriched with 292 edges in the PPI network, of which the top 10 hub genes were CD4, IL7R, CD3E, CD5, CD247, KLRB1, CD40LG, CD7, CR2, and GZMK. Furthermore, the study found 48 transcription factors and 8 microRNAs regulating these hub genes. Finally, four drugs namely ibalizumab (targeted to CD4), blinatumomab (targeted to CD3E), muromonab-CD3 (targeted to CD3E), and catumaxomab (targeted to CD3E) were found in gene-drug interaction.ConclusionFour possible drugs that targeted two specific genes, which may be beneficial for COVID-19 patients with SLE. (1) This study sought to analyze the potential molecular connections between COVID-19 and systemic lupus erythematosus (SLE), employing a bioinformatics approach to identify effective drugs for both conditions. (2) Four drugs namely ibalizumab (targeted to CD4), blinatumomab (targeted to CD3E), muromonab-CD3 (targeted to CD3E), and catumaxomab (targeted to CD3E) were found. (3) Four possible drugs that targeted two specific genes, which may be beneficial for COVID-19 patients with SLE.image
引用
收藏
页数:9
相关论文
empty
未找到相关数据